Trial · NCT00754325
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Disease Progression (PD) or Death | Fulvestrant and Dasatinib | 35 | participants | ||
| Number of Participants With Disease Progression (PD) or Death | Fulvestrant | 40 | participants | ||
| Median Time of Progression-free Survival (PFS) | Fulvestrant and Dasatinib | 5.6 | 95% Confidence Interval 3.6 to 9.3 | months | |
| Median Time of Progression-free Survival (PFS) | Fulvestrant | 5.3 | 95% Confidence Interval 3.0 to 7.4 | months | |
| Percentage of Participants With Progression Free Survival (PFS) at 6 Months | Fulvestrant and Dasatinib | 48.1 | 95% Confidence Interval 33.0 to 61.7 | percentage of participants | |
| Percentage of Participants With Progression Free Survival (PFS) at 6 Months | Fulvestrant | 44.6 | 95% Confidence Interval 30.1 to 58.1 | percentage of participants | |
| Percentage of Participants With Clinical Benefit for At Least 6 Months | Fulvestrant and Dasatinib | 38.0 | 95% Confidence Interval 24.7 to 52.8 | percentage of participants | |
| Percentage of Participants With Clinical Benefit for At Least 6 Months | Fulvestrant | 42.9 | 95% Confidence Interval 28.8 to 57.8 | percentage of participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant and Dasatinib | Complete Response, CR | 0 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant | Complete Response, CR | 0 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant and Dasatinib | Partial Response, PR | 1 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant | Partial Response, PR | 3 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant and Dasatinib | Stable Disease, SD | 34 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant | Stable Disease, SD | 28 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant and Dasatinib | Disease Progression, PD | 11 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant | Disease Progression, PD | 16 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant and Dasatinib | Not Evaluable | 4 | participants | |
| Number of Participants With Complete Response (CR) , Partial Response (PR), Stable Disease (SD), and Disease Progression (PD) | Fulvestrant | Not Evaluable | 2 | participants | |
| Number of Participants With Best Overall Response | Fulvestrant and Dasatinib | 1 | participants | ||
| Number of Participants With Best Overall Response | Fulvestrant | 2 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00754325/results